Marshall Wace’s Eterna Therapeutics ERNA Stock Holding History

Marshall Wace’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9	Closed	-$138K	–	3538
2022 Q1	$138K	Buy	9 +5	+125%	+$94.9K	﹤0.01%	3152
2021 Q4	$138K	Buy	+4	New	+$218K	﹤0.01%	3288

Other funds holding ERNA

CPWM

Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return

Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Inverness Counsel New York $1.8B AUM 9.9% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace's ERNA Position: Q2 2022 in Review

Marshall Wace sold out of Eterna Therapeutics (ERNA) in Q2 2022, closing a stake of 9 shares — an estimated $138K sold.

Marshall Wace first reported a position in ERNA in Q4 2021 and held it in 2 quarters. The position peaked at $138K in Q1 2022. 34 funds tracked by Wall St. Rank hold ERNA as of Q2 2022.

Marshall Wace reported no remaining Eterna Therapeutics position as of Q2 2022 after selling out during the quarter.
Marshall Wace sold 9 Eterna Therapeutics shares in Q2 2022, an estimated $138K.
Marshall Wace first reported a position in Eterna Therapeutics in Q4 2021 and held it in 2 quarters.
Marshall Wace's Eterna Therapeutics position peaked at $138K in Q1 2022.
34 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q2 2022.

Based on Marshall Wace's 13F filing for Q2 2022, filed 15 Aug 2022.